---
title: "MeiraGTx Signs Exclusive License Agreement With ZipBio for Geographic Atrophy Gene Therapy"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274660684.md"
datetime: "2026-02-03T13:03:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274660684.md)
  - [en](https://longbridge.com/en/news/274660684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274660684.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274660684.md) | [English](https://longbridge.com/en/news/274660684.md)


# MeiraGTx Signs Exclusive License Agreement With ZipBio for Geographic Atrophy Gene Therapy

MeiraGTx Holdings plc has entered into an exclusive license agreement with ZipBio, a biotechnology company specializing in AI-driven protein therapeutics. Under the terms of the agreement, MeiraGTx will gain exclusive rights to develop and commercialize ZipBio’s first-in-class therapies for Geographic Atrophy, which target the complement pathway. The collaboration combines MeiraGTx’s expertise in genetic medicine development and manufacturing with ZipBio’s proprietary AI-based protein design platform, COMPACT™. The agreement includes upfront, milestone, and royalty payments, though specific financial terms were not disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY76566) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [TG Therap (TGTX.US)](https://longbridge.com/zh-HK/quote/TGTX.US.md)
- [MeiraGTx (MGTX.US)](https://longbridge.com/zh-HK/quote/MGTX.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)

## 相關資訊與研究

- [BUZZ-Tempus AI rises after study shows AI-driven alerts improve heart valve treatment](https://longbridge.com/zh-HK/news/281390073.md)
- [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/zh-HK/news/280909399.md)
- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/zh-HK/news/281186075.md)
- [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/zh-HK/news/281024362.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/zh-HK/news/281174211.md)